• Looking at Drug Development
    Through New Eyes

  • Sylentis
    RNAi Technology:





  • Focused on
    Ophthalmic RNAi Therapies

  • Follow us on LINKEDIN

Welcome

Sylentis was founded in 2006 as a spin-off within the Zeltia Group, with the mission of building a solid and sustainable business and becoming a therapeutic platform based on RNA interference.

Sylentis’ pipeline is directed towards indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases.

Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy has consisted on first selecting accessible therapeutic targets, which don’t require systemic administration of the product. However, the development of formulations which will allow systemic administration without the risk of secondary effects, is an area of great interest to the company.